Dashboard
Manage Tickers

SLS SELLAS Life Sciences Group,...

Nasdaq sellaslifesciences.com


$ 2.02 $ -0.13 (-6.07 %)    

Monday, 20-Oct-2025 19:59:19 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 2.01
$ 2.43
$ 2.01 x 660
$ 2.11 x 100
$ 2.00 - $ 2.48
$ 0.77 - $ 2.48
19,338,159
na
211.65M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-23-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-13-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 03-22-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 04-13-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

sellas-life-sciences-gr-option-alert-feb-20-25-calls-sweep-37-near-the-ask-6320--0601-vs-0-oi-earnings-1112-after-close-est-ref2
SELLAS Life Sciences Gr Option Alert: Feb ...
10/14/2025 15:43:48

sellas-life-sciences-to-present-preclinical-efficacy-of-highly-selective-cdk9-inhibitor-sls009-as-monotherapy-and-in-combination-with-venetoclax-in-t-cell-prolymphocytic-leukemia-at-esmo-congress-2025
SELLAS Life Sciences To Present Preclinica...
10/13/2025 12:09:38

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharma...

sellas-life-sciences-group-files-for-offer-and-resale-by-selling-stockholders-up-to-19685040-shares-of-common-stock
SELLAS Life Sciences Group Files For Offer...
10/10/2025 20:13:07

https://www.sec.gov/Archives/edgar/data/1390478/000110465925098711/tm2528102d1_s3.htm

sellas-life-sciences-group-announces-exercise-of-warrants-held-by-institutional-investor-to-purchase-up-to-19685040-shares-for-gross-proceeds-236m
SELLAS Life Sciences Group Announces Exerc...
09/11/2025 12:36:41

sellas-life-sciences-gr-option-alert-jan-2027-25-calls-sweep-97-near-the-ask-1155--0451-vs-8362-oi-ref1785
SELLAS Life Sciences Gr Option Alert: Jan,...
08/20/2025 14:02:33

sellas-life-sciences-gr-q2-eps-007-beats-008-estimate
SELLAS Life Sciences Gr Q2 EPS $(0.07) Bea...
08/12/2025 20:28:44

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate o...

sellas-life-sciences-announces-independent-data-monitoring-committee-recommended-to-continue-phase-3-regal-trial-without-modification
SELLAS Life Sciences Announces Independent...
08/07/2025 12:33:59

maxim-group-maintains-buy-on-sellas-life-sciences-gr-raises-price-target-to-7
Maxim Group Maintains Buy on SELLAS Life S...
07/16/2025 18:32:09

Maxim Group analyst Jason McCarthy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and raises the price target fro...

sellas-life-sciences-says-phase-2-trial-of-sls009-tambiciclib-met-all-primary-endpoints-in-relapsedrefractory-acute-myeloid-leukemia
Sellas Life Sciences Says Phase 2 Trial Of...
07/15/2025 11:47:14

The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia...

sellas-life-sciences-to-be-added-to-russell-3000-and-russell-2000-indexes-effective-june-27-as-part-of-2025-russell-indexes-annual-reconstitution
SELLAS Life Sciences To Be Added To Russel...
06/24/2025 12:01:14

sellas-life-sciences-doses-first-pediatric-aml-patient-in-ongoing-phase-2-trial-of-sls009-rr-aml
SELLAS Life Sciences Doses First Pediatric...
05/15/2025 12:51:11

sellas-life-sciences-gr-q1-eps-007-beats-010-estimate
SELLAS Life Sciences Gr Q1 EPS $(0.07) Bea...
05/13/2025 20:30:55

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate o...

sellas-life-sciences-presents-preclinical-efficacy-of-sls009-in-tp53-mutated-aml-cells-at-aacr-conference
Sellas Life Sciences Presents Preclinical ...
04/28/2025 12:47:52

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceuti...

sellas-life-sciences-group-announced-cohort-3-data-from-ongoing-phase-2-trial-of-sls009-in-rr-aml
SELLAS Life Sciences Group Announced Cohor...
04/08/2025 12:50:11

sellas-life-sciences-gr-fy-2024-gaap-eps-050-beats-054-estimate
SELLAS Life Sciences Gr FY 2024 GAAP EPS $...
03/20/2025 20:15:58

sellas-announces-data-from-phase-2a-trial-of-sls009-in-combination-with-zanubrutinib-in-dlbcl-combination-achieved-a-67-of-overall-response-rate-median-overall-survival-not-reached-yet-67-of-patients-still-alive
SELLAS Announces Data From Phase 2a Trial ...
02/20/2025 13:47:00

- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in...

sellas-life-sciences-group-announces-25m-registered-direct-offering-of-19685040-shares-of-its-common-stock-and-warrants-to-purchase-up-to-an-aggregate-of-19685040-shares-of-common-stock-in-a-registered-direct-offering-at-a-combined-purchase-price-of-127-per-share-and-accompanying-warrant
SELLAS Life Sciences Group Announces $25M ...
01/28/2025 20:13:18

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceuti...

sellas-life-sciences-ceo-dr-angelos-stergiou-to-appear-on-fox-business-at-150-pm-et
SELLAS Life Sciences CEO Dr. Angelos Sterg...
01/24/2025 16:41:24

https://x.com/SellasLife/status/1882827755298918684

sellas-life-sciences-shares-are-trading-higher-after-the-company-announced-interim-analysis-results-from-its-phase-3-regal-trial-of-gps-in-acute-myeloid-leukemia
Sellas Life Sciences shares are trading hi...
01/23/2025 13:17:34

sellas-life-sciences-announces-interim-analysis-for-phase-3-regal-trial-of-gps-in-acute-myeloid-leukemia-showing-says-independent-data-monitoring-committee-recommended-trial-continue-without-modifications
SELLAS Life Sciences Announces Interim Ana...
01/23/2025 13:13:06

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION